Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Fig. 3

Kaplan-Meier estimates of overall survival (a) and progression free survival (b) in patients with and without a complete pathologic complete response. c and d are Kaplan-Meier estimates of overall surival (c) and progression free survival (d) of four groups based on pathologic staging (AJCC, 5th Edition). The four groups are patients with a pathologic complete response, microscopic residual disease or stage I, stage II, or stage III/IV cancers by pathologic staging

Back to article page